title: Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
authors.forename: S
authors.initials: S
authors.lastname: Manier
authors.forename: M
authors.initials: M
authors.lastname: Barthelemy
authors.forename: G
authors.initials: G
authors.lastname: Fouquet
authors.forename: C
authors.initials: C
authors.lastname: Prod'homme
authors.forename: E
authors.initials: E
authors.lastname: Le Ray
authors.forename: P
authors.initials: P
authors.lastname: Samarcq
authors.forename: M P
authors.initials: MP
authors.lastname: Noel
authors.forename: L
authors.initials: L
authors.lastname: Terriou
authors.forename: T
authors.initials: T
authors.lastname: Facon
authors.forename: C
authors.initials: C
authors.lastname: Cossment
authors.forename: F
authors.initials: F
authors.lastname: Boulanger
authors.forename: X
authors.initials: X
authors.lastname: Leleu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D013234:Stem Cells / Q000187:drug effects*; D013792:Thalidomide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D014750:Vincristine; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin